Company news

Sandoz Group Ltd news in 2026

Sandoz Group Ltd's news releases, calls and decks from 2026, newest first.

View company

Sandoz reports strong biosimilar-sales momentum; narrowed full-year net-sales range and upgrade to margin guidance

October 28, 2026

Sandoz opens advanced high-volume drug substance manufacturing centre in Lendava, significantly strengthening in-house capacity and flexibility across leading European biosimilar network

September 29, 2026

Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines

September 18, 2026

Sandoz issues EUR 500 million bond

September 14, 2026

Sandoz invests in new drug substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity

September 8, 2026

Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline

August 16, 2026

Sandoz delivers strong H1 2026 results, with outstanding biosimilar growth in the second quarter

August 5, 2026

Sandoz takes further steps to resolve legacy US generic medicine litigation

August 3, 2026

Sandoz confirms regulatory approval for new semaglutide treatment option in Brazil, paving way to expand patient access

July 29, 2026

Sandoz announces key leadership changes

July 15, 2026

Sandoz moves up Swiss equity rankings to join premier Swiss Market Index

July 9, 2026

Sandoz to Host Capital Markets Day: Maximising Sandoz Value in Its Golden Decade for Biosimilars

June 22, 2026

Sandoz steps up in-house biosimilar capabilities, opening state-of-the-art development centre to capture ‘golden decade’ opportunity

June 17, 2026

Sandoz marks 80 years of antibiotics with call for urgent political action to safeguard European medicine security

May 28, 2026

Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes

May 15, 2026

Sandoz climate targets validated by Science Based Targets initiative (SBTi)

May 5, 2026

Sandoz reports strong biosimilars growth in Q1 2026; full-year 2026 guidance confirmed

April 29, 2026

Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets

April 15, 2026

Shareholders approve all resolutions proposed by Board of Directors at 2026 Annual General Meeting of Sandoz Group AG

April 9, 2026

Q1 - (260401 Sandoz Aide Memoire)

April 2, 2026

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

March 18, 2026

Sandoz issues CHF 550 million in bonds and extends its USD 2 billion revolving credit facility by one year

March 11, 2026

Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth

March 10, 2026

Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth

February 25, 2026

Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology

February 23, 2026

Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications

February 18, 2026

Sandoz Canada launches first ophthalmology biosimilar

February 2, 2026

Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes

January 14, 2026

Sandoz CEO, Speaking at 44th Annual J.P. Morgan Healthcare Conference, Will Outline Plans to Capitalize on Unprecedented Golden Decade of Affordable Medicines Opportunity

January 12, 2026

Calls in 2026

Decks in 2026